Volume 10, Issue 2 (In Press 2022)                   J. Pediatr. Rev 2022, 10(2): 8-8 | Back to browse issues page


XML Print


1- Associate Professor Arak University of Medical Sciences, Arak, Iran. , drghandi1351@gmail.com
2- General Physicians Arak University of Medical Sciences, Arak, Iran.
Abstract:   (242 Views)
Background: Antimonial compounds are the most common choice for treatment of cutaneous Leishmaniosis (CL). Antimonial toxicities are common and cardiac toxicity is one of them, which leads to electrocardiogram ECG changes. In this study, ECG changes in a patient with CL, who received systemic glucantime, were evaluated.
Case Presentation: A 7-year -old girl was admitted to Amir-Kabir Hospital with the complaint of skin lesions (CL) on her left leg from 10 months ago. The patient had received glucantime (10-20 mg/ kg/day) as a treatment for two 15-day periods and unfortunately, she has not responded to the treatment. Due to the cardiac side effects of glucantime, cardiology consultation was requested and an ECG was performed for the patients during the administration of treatment for the third time. Several ECG changes were detected including first-degree block, Right bundle branch block, and QTc prolongation. The cardiologist stopped the treatment with glucantime to improve the ECG changes, and an electrocardiogram was taken every week.  Even though prolonged QT interval and RBBB improved after a month, the first-degree block was present for 10 months.
Conclusions: . It shows the necessity of ECG monitoring prior and during the treatment with this drug. Moreover, RBBB has not commonly reported in other studies. Thus, it should be considered as one of the cardiac side effects of glucantime and needs more attention.
 
     
Type of Study: Case Report and Review of Literature | Subject: Cardiology
Received: 2021/02/14 | Accepted: 2022/04/20 | Published: 2022/04/25

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.